http://www.lsis.com/goto/r99/rss 2010-06-23T11:10:59+01:00 text/html http://www.ncbi.nlm.nih.gov NCBI PubMed http://www.lsis.com/goto/v99/%3B%97f%FB%1Dt%7Es J Control Release. |-| Lipp R, Mrsny R, Park K. |-| Lilly Research Laboratories, Eli Lilly and Company, Indianapolis, Indiana 46285, U.S.A. text/html http://www.businesswire.com Business Wire http://www.lsis.com/goto/v99/%3B%97f%FB%11tv%7E DUBLIN-(BUSINESS WIRE)-Research and Markets (http:/www.researchandmarkets.com/research/f528a3/eli_lilly_and_comp) has announced the addition of the "Eli Lilly and Company - SWOT Analysis" company profile to their offering. Eli Lilly and Company - SWOT Analysis The Eli Lilly and Company - SWOT Analysis company profile is the essential source for top-level company data and information. Eli Lilly and Company - SWOT Analysis examines the company's key business structure and operations, history and products, and provides summary analysis of its key revenue lines and strategy. Eli Lilly (Lilly) is one of the largest global, research-based pharmaceutical companies. The company's primary (…) text/html http://www.medicalnewstoday.com Medical News Today http://www.lsis.com/goto/v99/%3B%97f%FB%11z%7D%7F Amylin Pharmaceuticals, Inc. (Nasdaq: AMLN), Eli Lilly and Company (NYSE: LLY) and Alkermes, Inc. (Nasdaq: ALKS) today announced results from DURATION-4, the fourth in a series of studies designed to test the superiority of BYDUREON (exenatide extended-release for injectable suspension), an investigational type 2 diabetes therapy, as compared to other type 2 diabetes medications. This 26-week clinical study compared BYDUREON monotherapy to Januvia (sitagliptin), Actos (pioglitazone HCI) or metformin, three oral type 2 diabetes medications commonly prescribed early in the treatment of type 2 diabetes. Study participants were not achieving adequate A1C control using diet and exercise, (…) text/html http://www.ncbi.nlm.nih.gov NCBI PubMed http://www.lsis.com/goto/v99/%3B%97f%FB%17%7Bvy Several analytical approaches were used to characterize time progression of weight changes observed in adults treated with olanzapine from a 12,425-patient database of 86 studies of oral and depot formulations of olanzapine (mean modal dose 13.3 mg/day). Descriptive mean profile plots for completer and modified completer groups showed weight increasing throughout each observed period, with apparent slowing in rate of change after 3 or 4 months. Mixed-effects model repeated measures analyses also showed that weight increased most rapidly early in treatment and slowed within 2 to 4 months. The slowing in rate of change was greatest for patients obese at baseline and least for patients (…) text/html http://www.businesswire.com Business Wire http://www.lsis.com/goto/v99/%3B%97f%FB%14%7E%7F%7D DUBLIN-(BUSINESS WIRE)-Research and Markets (http:/www.researchandmarkets.com/research/d7d20e/discovery_stage_pa) has announced the addition of the "Discovery Stage Partnering Terms and Agreements in Pharma, Biotech and Diagnostics, 2nd Edition" report to their offering. Discovery Stage Partnering Terms and Agreements in Pharma, Biotech and Diagnostics, 2nd Edition The Discovery Stage Partnering Terms and Agreements in Pharma and Biotech report detailed understanding and analysis of how and why companies enter discovery stage licensing/business development and other forms of partnering arrangement. The report provides a detailed understanding and analysis of how and why companies enter (…) text/html http://www.ncbi.nlm.nih.gov NCBI PubMed http://www.lsis.com/goto/v99/%3B%97f%FB%14%7D%7Dr We designed primers and probes for detection and discrimination of Ureaplasma parvum and U. urealyticum and their 14 serovars by real-time PCR. Analytical sensitivity and specificity for the multiplex species-specific PCR were determined by testing corresponding American Type Culture Collection (ATCC) type strains, 47 other microbial species, and human genomic DNA. The limits of the multiplex PCR were 2.8x10(-2) CFU/mul PCR mixture for detecting U. parvum and 4.1x10(-2) CFU/mul PCR mixture for detecting U. urealyticum. Clinical specificity and sensitivity were proven by comparison with culture and traditional PCR. For detection of any Ureaplasma species, the clinical sensitivity and (…) text/html http://www.ncbi.nlm.nih.gov NCBI PubMed http://www.lsis.com/goto/v99/%3B%97f%FC%1D%7F%7E%7C Historically, oral phosphodiesterase type 5 inhibitors (PDE5-i) have been prescribed with an 'as-necessary' regimen for treating erectile dysfunction (ED), thus addressing primarily symptom relief. However, approximately 30% of patients are unresponsive to on-demand PDE5-i regimens due to both psychogenic and organic factors and, although it is difficult to estimate the proportion, discontinuation rates remain high. In recent years, a 2.5-5 mg daily dose of tadalafil has been proposed and was recently approved for treating ED. Chronic PDE-5 inhibition has the advantage of potentially 'curing' ED, on a daily basis, by interfering with pathophysiological factors of both psychogenic (anxiety (…) text/html http://www.businesswire.com Business Wire http://www.lsis.com/goto/v99/%3B%97f%FC%12%7D%7Br NEWTON, Mass.-(BUSINESS WIRE)-Aircuity, the smart airside efficiency company, today announced that it will be attending the annual California Higher Education Sustainability Conference, taking place this year from June 20-23 at the Los Angeles Trade-Technical College. Aircuity will be joined in booth #133 by its partner, The George Yardley Company, a provider of engineered solutions for HVAC, plumbing and process piping applications to industrial and commercial businesses in Southern California, Arizona, New Mexico, Nevada and West Texas. WHAT: The 2010 California Higher Education Sustainability Conference WHO: Brady Nations, regional manager, Aircuity Rob Yardley, president, The George (…) text/html http://www.ncbi.nlm.nih.gov NCBI PubMed http://www.lsis.com/goto/v99/%3B%97f%FC%14u%7E%7C OBJECTIVE: To assess the maintenance of the effect of duloxetine in the treatment of chronic low back pain. METHODS: Patients (N = 181) with chronic low back pain entered a 41-week extension phase after completing a 13-week placebo-controlled treatment phase. The maintenance of the effect was assessed in patients taking duloxetine 60/120 mg/day who met the response criteria ( or = 30% reduction in Brief Pain Inventory average pain) at the end of the placebo-controlled phase. In addition, physical function was evaluated using the Roland-Morris Disability Questionnaire, the Clinical Global Impressions-Severity of Illness, and the Brief Pain Inventory Pain Severity and Interference ratings. (…) text/html http://www.biospace.com BioSpace http://www.lsis.com/goto/v99/%3B%97f%FD%1C%7B%7F%7C MECHELEN, BELGIUM-(Marketwire - June 17, 2010) - Galapagos NV (Euronext: GLPG) announced that Kempen and Co. placed nearly 1.3 million Galapagos shares (5.4% of total outstanding shares) through an accelerated bookbuilding today. These shares were held by Apax, who obtained their position in Galapagos through the venture capital financing round in 2002. The shares were placed with European institutional investors. "I am very pleased that there is so much institutional investor interest in Galapagos and that this placement could be executed in only a couple of hours. We thank Apax for their support as a shareholder over the past eight years and welcome the new shareholders," said Onno van (…) text/html http://www.businesswire.com Business Wire http://www.lsis.com/goto/v99/%3B%97f%FD%1Cxy%7C WILMINGTON, N.C.-(BUSINESS WIRE)-PPD, Inc. (Nasdaq: PPDI) today announced it has appointed Mike Wilkinson, Ph.D., as executive vice president and chief information officer and Paul Colvin as executive vice president of global clinical development effective June 30. Our efforts are focused on offering our clients a diverse and refined portfolio of services to better address the needs and requirements they face both today and in the future As executive vice president and chief information officer, Dr. Wilkinson will provide strategic direction for PPD s development and deployment of innovative ideas and technology and will oversee the integration of technology initiatives with process (…) text/html http://www.businesswire.com Business Wire http://www.lsis.com/goto/v99/%3B%97f%FD%1Cx%7C%7B CHAPEL HILL, N.C.-(BUSINESS WIRE)-POZEN Inc. (NASDAQ: POZN), today announced the election of Neal F. Fowler to its Board of Directors at the Annual Meeting of Shareholders held on June 10, 2010. Mr. Fowler is Chief Executive Officer of Liquidia Technologies, Inc. Mr. Fowler joined Liquidia in 2008 after seven successful years at Johnson & Johnson (J&J). While at J&J, Mr. Fowler served as President of Centocor, Inc., a multi-billion dollar subsidiary focused on development and commercialization of industry leading biomedicines used in the treatment of chronic inflammatory diseases. At Centocor, Mr. Fowler prepared the company for the launch of two potential blockbuster products and (…) text/html http://www.businesswire.com Business Wire http://www.lsis.com/goto/v99/%3B%97f%FD%1C%7Fyr SAN DIEGO & INDIANAPOLIS & WALTHAM, Mass.-(BUSINESS WIRE)-Amylin Pharmaceuticals, Inc. (Nasdaq: AMLN), Eli Lilly and Company (NYSE: LLY) and Alkermes, Inc. (Nasdaq: ALKS) today announced results from DURATION-4, the fourth in a series of studies designed to test the superiority of BYDUREON ¢ (exenatide extended-release for injectable suspension), an investigational type 2 diabetes therapy, as compared to other type 2 diabetes medications. DURATION-4 reinforced that a continued presence of exenatide helped these recently diagnosed patients to achieve glycemic control. The combination of efficacy, tolerability, and once weekly dosing in this monotherapy setting further supports the (…) text/html http://www.ncbi.nlm.nih.gov NCBI PubMed http://www.lsis.com/goto/v99/%3B%97f%FD%1Dtw%7E Background: Olanzapine (Eli Lilly and Company, Indianapolis, IN) is starting to be used with more frequency in emergency departments (EDs) for agitated patients. The potential complications of the use of olanzapine in combination with a benzodiazepine have not been well characterized in ED patients with undifferentiated agitation. Objectives: The measurement of vital signs, repeat medication dosage, and ethanol levels in patients who received parenteral (intramuscular [IM]) olanzapine either alone or concurrently with benzodiazepines. Methods: This is a structured retrospective chart review of all patients who met the criteria of having received IM olanzapine for agitation and having vital (…) text/html http://www.biospace.com BioSpace http://www.lsis.com/goto/v99/%3B%97f%FD%11z%7Cr CHAPEL HILL, N.C.-(BUSINESS WIRE)-POZEN Inc. (NASDAQ: POZN), today announced the election of Neal F. Fowler to its Board of Directors at the Annual Meeting of Shareholders held on June 10, 2010. Mr. Fowler is Chief Executive Officer of Liquidia Technologies, Inc. Mr. Fowler joined Liquidia in 2008 after seven successful years at Johnson & Johnson (J&J). While at J&J, Mr. Fowler served as President of Centocor, Inc., a multi-billion dollar subsidiary focused on development and commercialization of industry leading biomedicines used in the treatment of chronic inflammatory diseases. At Centocor, Mr. Fowler prepared the company for the launch of two potential blockbuster products and (…) text/html http://www.biospace.com BioSpace http://www.lsis.com/goto/v99/%3B%97f%FD%11y%7C%7B SAN DIEGO & INDIANAPOLIS & WALTHAM, Mass.-(BUSINESS WIRE)-Amylin Pharmaceuticals, Inc. (Nasdaq: AMLN), Eli Lilly and Company (NYSE: LLY) and Alkermes, Inc. (Nasdaq: ALKS) today announced results from DURATION-4, the fourth in a series of studies designed to test the superiority of BYDUREON ¢ (exenatide extended-release for injectable suspension), an investigational type 2 diabetes therapy, as compared to other type 2 diabetes medications. text/html http://www.businesswire.com Business Wire http://www.lsis.com/goto/v99/%3B%97f%FD%11%7Evr CAMBRIDGE, Mass.-(BUSINESS WIRE)-Outcome Sciences, Inc. (OUTCOME), the leading provider of patient registries, studies, and technologies for evaluating real-world outcomes, today announced that the June issue of the American Journal of Managed Care (AJMC) will feature an article entitled œGRACE Principles: Recognizing High-Quality Observational Studies of Comparative Effectiveness  written by Nancy A. Dreyer, PhD, and Richard E. Gliklich, MD, of Outcome; Sebastian Schneeweiss, MD, and Barbara J. McNeil, MD, of Harvard Medical School; Marc L. Berger, MD, of Eli Lilly and Company; Alec M. Walker, MD, of World Health Information Science Consultants; and Daniel A. Ollendorf, MPH, from the (…) text/html http://www.businesswire.com Business Wire http://www.lsis.com/goto/v99/%3B%97f%FD%11%7Exs WALTHAM, Mass.-(BUSINESS WIRE)-Phase Forward (NASDAQ: PFWD), a leading provider of data management solutions for clinical trials and drug safety, today announced its Central Coding ¢ application has become the first product to achieve certification by the Uppsala Monitoring Center (UMC). Launched today ( œUppsala Monitoring Centre Launches Software Certification Program for WHO Drug Dictionary Enhanced ), UMC s new certification is designed to help software developers quickly and easily integrate the WHO Drug Dictionary Enhanced. The WHO Drug Dictionary Enhanced is the world s most comprehensive dictionary of medicinal product information and the de facto standard for coding (…) text/html http://www.biospace.com BioSpace http://www.lsis.com/goto/v99/%3B%97f%FD%11%7D%7Cz CAMBRIDGE, Mass.-(BUSINESS WIRE)-Outcome Sciences, Inc. (OUTCOME), the leading provider of patient registries, studies, and technologies for evaluating real-world outcomes, today announced that the June issue of the American Journal of Managed Care (AJMC) will feature an article entitled œGRACE Principles: Recognizing High-Quality Observational Studies of Comparative Effectiveness  written by Nancy A. Dreyer, PhD, and Richard E. Gliklich, MD, of Outcome; Sebastian Schneeweiss, MD, and Barbara J. McNeil, MD, of Harvard Medical School; Marc L. Berger, MD, of Eli Lilly and Company; Alec M. Walker, MD, of World Health Information Science Consultants; and Daniel A. Ollendorf, MPH, from the (…) text/html http://www.ncbi.nlm.nih.gov NCBI PubMed http://www.lsis.com/goto/v99/%3B%97f%FD%16%7D%7D%7E AIM: To examine changes in patient-reported outcome (PRO) measures in patients with type 2 diabetes (T2DM) on oral agents who initiated insulin (insulin lispro mix 25/75 [LM25] or insulin glargine) in the DURABLE trial (n=580). METHODS: Subjects completed generic and diabetes-specific health-related quality-of-life measures (RAND-36 and Diabetes-39) and a symptom assessment measure (DSC-Revised) at baseline and 6 months post insulin initiation. Mean score change was evaluated. Effect size (ES; Cohen's d) and analysis of covariance were used to examine extent and significance of change both within and between treatment groups. RESULTS: Subject characteristics were mean age 57 years, males (…) text/html http://www.ncbi.nlm.nih.gov NCBI PubMed http://www.lsis.com/goto/v99/%3B%97f%FD%15y%7Ez Aims Self-monitoring of blood glucose (SMBG) is an important self-management tool for insulin-treated patients with Type 2 diabetes mellitus (T2DM). Its value in estimating glycaemic control in insulin-treated T2DM patients remains unclear. The relationship between glycated haemoglobin (HbA(1c) and SMBG measures in T2DM patients treated with premixed insulin lispro mixtures or basal insulin glargine was examined. Methods HbA(1c) and plasma equivalent glucose (PGe) data derived from SMBG profiles were pooled from five randomized clinical trials of patients with T2DM on one or more oral glucose-lowering medication +/- 0-2 insulin injections per day switching to insulin lispro mixtures (N = (…) text/html http://www.ncbi.nlm.nih.gov NCBI PubMed http://www.lsis.com/goto/v99/%3B%97f%FE%1D%7D%7Dz BACKGROUND: The objective of this project was to improve the timing of inpatient insulin administration related to meal delivery and the scheduling of radiology tests by Lean Six Sigma method. METHODS: A multidisciplinary hospital team and a Six Sigma team from a pharmaceutical manufacturer collaborated to evaluate food delivery and radiology scheduling processes related to the timing of insulin administration. Key factors leading to problems within each system were addressed to improve the efficiency of each process while improving the timeliness of glucose testing and insulin administration. RESULTS: Standardizing the food delivery schedule and utilizing scorecards to track on-time meal (…) text/html http://www.marketwire.com Marketwire http://www.lsis.com/goto/v99/%3B%97f%FE%12y%7Fx CALGARY, ALBERTA-(Marketwire - June 9, 2010) - Acceleware Corp. (TSX VENTURE:AXE) a leading developer of high performance computing (HPC) applications, today announced a new partnership with Paradigm" (http:/www.pdgm.com/), a leading provider of enterprise software solutions to the global oil and natural gas exploration and production industry, to deliver a full-wave Reverse Time Migration (RTM) solution that incorporates Acceleware's RTM product, AxRTM" optimized for clusters of multi-core CPUs and GPUs. "This partnership was established to carry out our ongoing commitment to provide the oil and gas industry with high quality and efficient high performance computing seismic imaging (…) text/html http://www.businesswire.com Business Wire http://www.lsis.com/goto/v99/%3B%97f%FE%12%7Dzx SAN RAMON, Calif.-(BUSINESS WIRE)-Nextrials, Inc. (www.nextrials.com), a leader in clinical research software and services, today announced that its electronic data capture (EDC) and clinical trial data management platform, Prism ¢, is now integrated with the study design tools offered by Formedix. Formedix s industry leading Origin ¢ products include database design tools based on the data standards developed by the Clinical Data Interchange Standards Consortium (CDISC), a platform that Nextrials fully supports. In fact, both Nextrials and Formedix are CDISC Registered Solutions Providers. With this strategic partnership, Prism users can now easily build customized databases in just a (…) text/html http://www.businesswire.com Business Wire http://www.lsis.com/goto/v99/%3B%97f%FE%13uwy DUBLIN-(BUSINESS WIRE)-Research and Markets (http:/www.researchandmarkets.com/research/3ff3ce/pharmaceutical_ind) has announced the addition of the "Pharmaceutical Industry in Mexico" report to their offering. Over the past decade, pharmaceutical companies have pushed the scientific envelope, working at the cellular and molecular levels to dramatically advance the treatment of disease. Mexico's pharmaceutical policy environment is in a period of rapid evolution, with simultaneous policy development, refinement and ongoing implementation. This handicaps Mexico's efforts to achieve policy goals efficiently at the present time, and also makes policy assessment and even accurate description (…) text/html http://www.ncbi.nlm.nih.gov NCBI PubMed http://www.lsis.com/goto/v99/%3B%97f%FE%16%7D%7D%7E Data from the EMBLEM Study, a 2-year, prospective, observational study of health outcomes associated with acute treatment of patients experiencing a manic/mixed episode of bipolar disorder, was used to compare the effectiveness of olanzapine monotherapy versus risperidone monotherapy, and to investigate whether the treatment effects were similar to those reported in a 3-week, randomized controlled trial assessing the same treatments. Symptom severity measures included the Young Mania Rating Scale (YMRS), the 5-item Hamilton Depression Rating Scale, and the Clinical Global Impression-Bipolar Disorder Scale. A total of 245 EMBLEM inpatients were analyzed with YMRS /=20: olanzapine (n=209), (…) text/html http://www.ncbi.nlm.nih.gov NCBI PubMed http://www.lsis.com/goto/v99/%3B%97f%FE%16%7D%7By Clin Pharmacol Ther. |-| Allerheiligen SR. |-| Lilly Research Laboratories, Eli Lilly and Company, Indianapolis, Indiana, USA. text/html http://www.biospace.com BioSpace http://www.lsis.com/goto/v99/%3B%97f%FF%12%7C%7Cz Bloomberg - Eli Lilly & Co. and Merck KGaA s Erbitux, approved for advanced colon cancer, failed to slow tumors in a study designed to expand the medicine s use to patients whose disease is in an earlier stage. text/html http://www.ncbi.nlm.nih.gov NCBI PubMed http://www.lsis.com/goto/v99/%3B%97f%FF%11uyr Mianowska B, Szadkowska A, Pietrzak I, Zmys?owska A, Wegner O, Tomczonek J, Bodalski J, M?ynarski W. Immunogenicity of different brands of human insulin and rapid-acting insulin analogs in insulin-naïve children with type 1 diabetes. Aims: To determine (i) whether insulin preparations produced by three companies induce the same immune responses in insulin-naïve children with type 1 diabetes (T1DM); (ii) if switching from human insulin to rapid-acting insulin analogs influences this immune response; and (iii) if different insulin brands produce different clinical results during the first 2 yr after T1DM diagnosis. Methods: Insulin antibodies (IA) were measured for 140 patients aged (…) text/html http://www.businesswire.com Business Wire http://www.lsis.com/goto/v99/%3B%97f%FF%11%7F%7E%7B SAN MATEO, Calif.-(BUSINESS WIRE)-Deltagen, Inc. (Pink Sheets:DGEN), a leading provider of drug discovery tools to the biopharmaceutical industry, today reported unaudited consolidated financial results for the three months ended March 30, 2010. Management s Discussion and Analysis of Financial Conditions and Results of Operations Revenues: The Company s consolidated revenues for the three months ended March 30, 2010 totaled $0.499 million. The revenues in the first quarter were attributable primarily to license fees associated with the provision of knockout mice and related phenotypic data pursuant to orders placed by customers under the Company s DeltaOneTM program. Interest Income: (…) text/html http://www.businesswire.com Business Wire http://www.lsis.com/goto/v99/%3B%97f%FF%11%7Ev%7C ROCKVILLE, Md.-(BUSINESS WIRE)-Emergent BioSolutions Inc. (NYSE:EBS) announced today that the company s Board of Directors appointed Marvin White as a Class II Director for a one-year term that will expire at the 2011 annual meeting of stockholders. Mr. White s expertise in financial management, gained in a patient-focused health care system and service-oriented environment, will prove an invaluable asset in guiding Emergent s management team towards further growth and in increasing value for shareholders œMr. White s expertise in financial management, gained in a patient-focused health care system and service-oriented environment, will prove an invaluable asset in guiding Emergent s (…) text/html http://www.ncbi.nlm.nih.gov NCBI PubMed http://www.lsis.com/goto/v99/%3B%97f%FF%14zyy The use of centralized raters who are remotely linked to sites and interview patients via videoconferencing or teleconferencing has been suggested as a way to improve interrater reliability and interview quality. This study compared the effect of site-based and centralized ratings on patient selection and placebo response in subjects with major depressive disorder. Subjects in a 2-center placebo and active comparator controlled depression trial were interviewed twice at each of 3 time points: baseline, 1-week postbaseline, and end point-once by the site rater and once remotely via videoconference by a centralized rater. Raters were blind to each others' scores. A site-based score of (…) text/html http://www.businesswire.com Business Wire http://www.lsis.com/goto/v99/%3B%97f%FF%15uz%7E LONG BEACH, Calif. & CHICAGO-(BUSINESS WIRE)-A team of investigators at Rational Therapeutics, Inc. (http:/www.rationaltherapeutics.com) and the Malcolm Todd Cancer Institute (Long Beach, Calif.) has reported that functional profiling using ex-vivo analysis of programmed cell death (EVA/PCD) can be used to prescribe treatment regimens that double the response rate and survival in patients with Stage IV non-small cell lung cancer (NSCLC). The findings of their phase II clinical trial will be presented on Sunday, June 6th at the 46th Annual Meeting of the American Society of Clinical Oncology (ASCO) in Chicago. What makes the EVA/PCD approach unique is its capacity to capture human (…) text/html http://www.businesswire.com Business Wire http://www.lsis.com/goto/v99/%3B%97f%FF%15tws DUBLIN-(BUSINESS WIRE)-Research and Markets (http:/www.researchandmarkets.com/research/718e3b/united_states_diab) has announced the addition of GlobalData's new report "United States Diabetes Care Devices Market Outlook to 2016" to their offering. United States Diabetes Care Devices Market Outlook to 2016 Our new report, US Diabetes Care Devices Market Outlook to 2016 provides key market data on the US diabetes care devices market. The report provides value (USD million), volume (units) and average price (USD) data for each segment and sub-segment within two market categories - Glucose Monitoring and Insulin Delivery. The report also provides company shares and distribution shares data (…) text/html http://www.businesswire.com Business Wire http://www.lsis.com/goto/v99/%3B%97f%FF%15tv%7B DUBLIN-(BUSINESS WIRE)-Research and Markets (http:/www.researchandmarkets.com/research/f8bc26/option_and_evaluat) has announced the addition of the "Option and Evaluation Agreements in Pharma and Biotech, 2nd Edition" report to their offering. Option and Evaluation Agreements in Pharma and Biotech, 2nd Edition The Option and Evaluation Agreements in Pharma and Biotech report provides comprehensive understanding and unprecedented access to the option and evaluation partnering agreements entered into by the worlds leading biopharma companies. This report provides details of the latest option and evaluation agreements announced in the pharmaceutical and biotechnology sectors. Detailed and (…) text/html http://www.ncbi.nlm.nih.gov NCBI PubMed http://www.lsis.com/goto/v99/%3B%97f%FF%15%7B%7Cr The p38 MAPK is rapidly activated by stresses and is believed to play an important role in stress response. While Chk1 is known to mediate the G2 DNA damage checkpoint control, p38 is also reported to have an essential function in this checkpoint control. Here, we have investigated further the roles of p38 and Chk1 in G2 DNA damage checkpoint in cancer cells. We find that although p38 activation is strongly induced by DNA damage, its activity is not required for the G2 DNA damage checkpoint. By contrast, Chk1 kinase is responsible for the execution of G2 DNA damage checkpoint control in p53-deficient cells. Inhibition of p38 activity has no effect on Chk1 activation and gammaH2AX (…) text/html http://www.ncbi.nlm.nih.gov NCBI PubMed http://www.lsis.com/goto/v99/%3B%97f%FF%15%7Dx%7F Am J Psychiatry. |-| Ashton AK. |-| Dr. Ashton serves on the speaker's bureaus of AstraZeneca, Bristol-Myers Squibb, Cephalon, Eli Lilly, Forest, GlaxoSmithKline, Merck, PamLab, Pfizer, Sanofi-Aventis, Sepracor, and Symposia Medicus. text/html http://www.ncbi.nlm.nih.gov NCBI PubMed http://www.lsis.com/goto/v99/%3B%97f%FF%15%7C%7E%7B Abstract Alcoholism remains a serious cause of morbidity and mortality despite progress through neurobiological research in identifying new pharmacological strategies for its treatment. Drugs that affect neural pathways that modulate the activity of the cortico-mesolimbic dopamine system have been shown to alter drinking behavior, presumably because this dopaminergic system is closely associated with rewarding behavior. Ondansetron, naltrexone, topiramate, and baclofen are examples. Subtyping alcoholism in adults into an early-onset type, with chronic symptoms and a strong biological predisposition to the disease, and a late-onset type, typically brought on by psychosocial triggers and (…) text/html http://www.ncbi.nlm.nih.gov NCBI PubMed http://www.lsis.com/goto/v99/%3B%97g%F6%1Cx%7E%7C AIMS: To investigate the associations of HbA1c, fasting glucose, and postload plasma glucose with 10-year fatal and nonfatal cardiovascular disease (CVD) and all-cause mortality in Caucasian individuals between 50 and 75 years of age without diabetes. METHOD AND RESULTS: The 10-year risk of all-cause mortality and CVD in relation to HbA1c and glucose levels was assessed with Cox survival analysis in 1674 nondiabetic individuals of a population-based cohort (Hoorn Study). Analyses were stratified according to sex and adjustments were made for age and known CVD risk factors. After full adjustment, HbA1c levels /=6.0% were significantly associated with an increased risk of nonfatal CVD (…) text/html http://www.businesswire.com Business Wire http://www.lsis.com/goto/v99/%3B%97g%F6%12%7Fw%7C TEL AVIV, Israel-(BUSINESS WIRE)-The ILSI Biomed Israel 2010 Week, the key annual life sciences event in Israel, that will be launched on June the 13th, 2010, will hold this year professional seminars dealing with some of the hottest issues of the medical fields. Thirty two senior members of the world industry will come to Israel for the event and throughout the conference days will discuss the various subjects like Cardiology, the Development of New vaccines, the use of Stem Cells, Metabolic Disease, Personalized Medicine, Regulation, E-volving promises of efficiency and empowerment in healthcare and Oncology. Medical Innovation: From Idea to Bench to Bedside - A Biomedical Innovation (…) text/html http://www.businesswire.com Business Wire http://www.lsis.com/goto/v99/%3B%97g%F6%12%7F%7Bx DUBLIN-(BUSINESS WIRE)-Research and Markets (http:/www.researchandmarkets.com/research/eac7e4/portfolio_analytic) has announced the addition of the "Portfolio Analytics and Planning in the Breast Cancer Pipeline - Change is Around the Corner in a Highly Competitive Market Place" report to their offering. Portfolio Analytics and Planning in the Breast Cancer Pipeline - Change is Around the Corner in a Highly Competitive Market Place This report comprises defined and up to date development strategies for 405 breast cancer drugs within the portfolio of 220 investigators, from Ceased to Marketed. The report extensively analyses 207 identified targets of breast cancer drugs, organized into (…) text/html http://www.businesswire.com Business Wire http://www.lsis.com/goto/v99/%3B%97g%F6%12%7Ev%7F DUBLIN-(BUSINESS WIRE)-Research and Markets (http:/www.researchandmarkets.com/research/ed89f5/a_decision_support) has announced the addition of the "A Decision Support Tool for Optimizing the Prostate Cancer Pipeline: From Research and Development to Market" report to their offering. A Decision Support Tool for Optimizing the Prostate Cancer Pipeline: From Research and Development to Market This report comprises defined and up to date development strategies for 346 prostate cancer drugs within the portfolio of 198 investigators, from Ceased to Marketed. The report extensively analyses 202 identified targets of prostate cancer drugs, organized into 187 drug target strategies, and (…) text/html http://www.ncbi.nlm.nih.gov NCBI PubMed http://www.lsis.com/goto/v99/%3B%97g%F6%13u%7E%7E Insulin pens are developed to address specific needs of diabetes patients for their pens, such as ease of use, portability, and discreetness. Like many consumer-based products, the development of insulin pens can pose significant challenges to the development team in that they must balance substantial accuracy requirements with aesthetic desires. The HumaPen(R) Memoir team learned valuable lessons throughout the development process that may be worth highlighting. A keen understanding of the unmet needs of the patient population and a skillfully planned product generation map are critical to successful device development. A development team must decide whether to use a Quality Functional (…) text/html http://www.ncbi.nlm.nih.gov NCBI PubMed http://www.lsis.com/goto/v99/%3B%97g%F6%13ux%7F BACKGROUND: Limited data are available on the predictors of insulin delivery device choice. This study assessed the patient- and health-care-system-related factors that predict the initiation of one rapid-acting insulin analog (RAIA) delivery system over another. METHODS: A retrospective analysis using a claims database (January 1, 2007, through March 31, 2009) was conducted. Patients were required to be diagnosed with type 2 diabetes mellitus, and have /=12 months of continuous eligibility prior to their first prescription of a RAIA on or after January 1, 2008. The three cohorts in the study were vial/syringe (n = 6820), prefilled pen (n = 5840), and reusable pen (n = 2052). Multiple (…) text/html http://www.biospace.com BioSpace http://www.lsis.com/goto/v99/%3B%97g%F6%10zz%7E Datamonitor attended this year's International Osteoporosis Foundation World Congress on Osteoporosis and 10th European Congress on Clinical and Economical Aspects of Osteoporosis and Osteoarthritis, the most important meeting on the osteoporosis calendar. A number of major pharmaceutical firms had a presence at the meeting, indicating the significance of this market. Pfizer: remains a small presence in the osteoporosis market The presence of Pfizer at the congress suggests that the company intends to launch Conbriza (bazedoxifene) in the European market after it was approved in 2009. It is Datamonitor's understanding that the company is negotiating price and reimbursement issues prior to (…) text/html http://www.businesswire.com Business Wire http://www.lsis.com/goto/v99/%3B%97g%F6%10%7Fxx NEWTON, Mass.-(BUSINESS WIRE)-Aircuity, the smart airside efficiency company, today announced that its customer, The Plant Conservation Science Center at the Chicago Botanic Garden in Glencoe, IL, has been selected as the 2010 Laboratory of the Year in R&D Magazine s annual competition. Aircuity was also recognized as a key player in the Texas Children s Hospital, Feigin Center expansion project, which received honorable mention in the competition. Aircuity s OptiNet system, a comprehensive suite of intelligent ventilation measurement and optimization technologies, was implemented in both facilities as a way for the organizations to lower operating costs, improve safety and become more (…) text/html http://www.businesswire.com Business Wire http://www.lsis.com/goto/v99/%3B%97g%F6%10%7F%7Cs DUBLIN-(BUSINESS WIRE)-Research and Markets (http:/www.researchandmarkets.com/research/be304a/pancreatic_cancer) has announced the addition of GlobalData's new report "Pancreatic Cancer - Drug Pipeline Analysis and Market Forecasts to 2016" to their offering. Pancreatic Cancer - Drug Pipeline Analysis and Market Forecasts to 2016 Pancreatic Cancer - Drug Pipeline Analysis and Market Forecasts to 2016 The report is an essential source of information and analysis on the global pancreatic cancer market. The report identifies the key trends shaping and driving the market, and provides insights on the prevalent competitive landscape and the emerging players expected to significantly shift (…) text/html http://www.businesswire.com Business Wire http://www.lsis.com/goto/v99/%3B%97g%F6%10%7F%7Ez DUBLIN-(BUSINESS WIRE)-Research and Markets (http:/www.researchandmarkets.com/research/4baefe/poland_pharmaceuti) has announced the addition of the "Poland Pharmaceuticals and Healthcare Report Q3 2010" report to their offering. Poland Pharmaceuticals and Healthcare Report Q3 2010 The Poland Pharmaceuticals and Healthcare Report provides industry professionals and strategists, corporate analysts, pharmaceutical associations, government departments and regulatory bodies with independent forecasts and competitive intelligence on Poland's pharmaceuticals and healthcare industry. The Pharmaceuticals & Healthcare Business Environment Ratings for Q310 put Poland as the second most attractive (…) text/html http://www.businesswire.com Business Wire http://www.lsis.com/goto/v99/%3B%97g%F6%10%7Ev%7E DUBLIN-(BUSINESS WIRE)-Research and Markets (http:/www.researchandmarkets.com/research/fef303/spain_diabetes_car) has announced the addition of GlobalData's new report "Spain Diabetes Care Devices Market Outlook to 2016" to their offering. Spain Diabetes Care Devices Market Outlook to 2016 Spain Diabetes Care Devices Market Outlook to 2016 Summary Our medical device report offering, Spain Diabetes Care Devices Market Outlook to 2016 provides key market data on the Spain diabetes care devices market. The report provides value (USD million), volume (units) and average price (USD) data for each segment and sub-segment within two market categories - Glucose Monitoring and Insulin Delivery. (…) text/html http://www.businesswire.com Business Wire http://www.lsis.com/goto/v99/%3B%97g%F6%10%7E%7D%7D DEERFIELD, Ill.-(BUSINESS WIRE)-Baxter International Inc. (NYSE:BAX) announced today two executive changes. Robert M. Davis, has been appointed corporate vice president and president of Baxter s Renal business, filling a role vacated by Bruce H. McGillivray, who is retiring after 30 years of service to the company. Davis previously served as corporate vice president and chief financial officer for Baxter. Concurrent with this change, Robert J. Hombach has been named corporate vice president and chief financial officer. Hombach previously served as corporate vice president and treasurer for Baxter. œWe are grateful for Bruce s many contributions over his 30-year career at Baxter,  said (…)